Login to Pancreatic Cancer UK

Everolimus approved in scotland by SMC

Posted by: Research 24 May 2012

Everolimus has been approved in Scotland by the SMC for use in neuroendocrine pancreatic cancer. Having provided a joint submission with the NET patient foundation to the review of Everolimus, we're very pleased here at Pancreatic Cancer UK that the treatment has been recommended as another option for neuroendocrine tumours.

Nab -Paclitaxel

Click here to see the full announcement.